{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:20Z","timestamp":1792787900118,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000137"],"award-info":[{"award-number":["82000137"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82002118"],"award-info":[{"award-number":["82002118"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2020JJ4918"],"award-info":[{"award-number":["2020JJ4918"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2023JJ41021"],"award-info":[{"award-number":["2023JJ41021"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The identifying of B-cell lymphoma 2 (Bcl-2) as a therapeutic target has led to a paradigm shift in acute myeloid leukemia (AML) treatment. Pyroptosis is a novel antitumor therapeutic mechanism due to its cytotoxic and immunogenic effects. The combination of venetoclax and hypomethylating agents (HMAs) has been shown to lead to durable responses and significantly improve prognosis in patients with AML. However, our understanding of the mechanisms underlying this combinatorial activity is evolving.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We investigated whether the Bcl-2 inhibitor venetoclax induces AML cell pyroptosis and identified pyroptosis effector proteins. Via using western blotting, immunoprecipitation, RNA interference, CCK8 assays, and LDH assays, we explored the mechanism underlying the pyroptotic effect. The relationship between the expression of the pyroptosis effector protein GSDME and AML prognosis was investigated. The effect of GSDME demethylation combined with venetoclax treatment on pyroptosis was investigated and confirmed in mouse models and clinical samples.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Venetoclax induces pyroptosis that is mediated by caspase-3-dependent GSDME cleavage. Mechanistically, venetoclax upregulates caspase-3 and GSDME cleavage by activating the intrinsic apoptotic pathway. GSDME is downregulated in AML by promoter methylation, and low GSDME expression is significantly associated with poor prognosis, based on public databases and patient sample analysis. In vivo and in vitro experiments showed that GSDME overexpression or HMAs-mediated restoration of GSDME expression significantly increased venetoclax-induced pyroptosis in AML.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>GSDME-mediated pyroptosis may be a novel aspect of the antileukemic effect of Bcl-2 inhibitors. This finding offers new insights into potential biomarkers and therapeutic strategies, identifying an important mechanism explaining the clinical activity of venetoclax and HMAs in AML.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-023-04481-0","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T16:03:39Z","timestamp":1694102619000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Antileukemic effect of venetoclax and hypomethylating agents via caspase-3\/GSDME-mediated pyroptosis"],"prefix":"10.1186","volume":"21","author":[{"given":"Fanghua","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenying","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6766-6577","authenticated-orcid":false,"given":"Liangchun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,7]]},"reference":[{"key":"4481_CR1","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392:593\u2013606.","journal-title":"Lancet"},{"key":"4481_CR2","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6: e441.","journal-title":"Blood Cancer J"},{"key":"4481_CR3","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"4481_CR4","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/ajh.25214","volume":"93","author":"EH Estey","year":"2018","unstructured":"Estey EH. Acute myeloid leukemia: 2019 update on risk-stratification and management. Am J Hematol. 2018;93:1267\u201391.","journal-title":"Am J Hematol"},{"key":"4481_CR5","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1182\/blood.V81.11.3091.3091","volume":"81","author":"L Campos","year":"1993","unstructured":"Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 1993;81:3091\u20136.","journal-title":"Blood"},{"key":"4481_CR6","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/335440a0","volume":"335","author":"DL Vaux","year":"1988","unstructured":"Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335:440\u20132.","journal-title":"Nature"},{"key":"4481_CR7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202\u20138.","journal-title":"Nat Med"},{"key":"4481_CR8","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a036400","author":"S Xia","year":"2020","unstructured":"Xia S, Hollingsworth LT, Wu H. Mechanism and regulation of gasdermin-mediated cell death. Cold Spring Harb Perspect Biol. 2020. https:\/\/doi.org\/10.1101\/cshperspect.a036400.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"4481_CR9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13046-021-01959-x","volume":"40","author":"Y Tan","year":"2021","unstructured":"Tan Y, Chen Q, Li X, Zeng Z, Xiong W, Li G, et al. Pyroptosis: a new paradigm of cell death for fighting against cancer. J Exp Clin Cancer Res. 2021;40:153.","journal-title":"J Exp Clin Cancer Res"},{"key":"4481_CR10","volume":"910","author":"MA Al","year":"2021","unstructured":"Al MA, Mimi AA, Aziz MA, Zaeem M, Ahmed T, Munir F, et al. Role of pyroptosis in cancer and its therapeutic regulation. Eur J Pharmacol. 2021;910: 174444.","journal-title":"Eur J Pharmacol"},{"key":"4481_CR11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.biochi.2021.03.007","volume":"185","author":"X Ju","year":"2021","unstructured":"Ju X, Yang Z, Zhang H, Wang Q. Role of pyroptosis in cancer cells and clinical applications. Biochimie. 2021;185:78\u201386.","journal-title":"Biochimie"},{"key":"4481_CR12","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3324\/haematol.2016.159160","volume":"102","author":"C Bi","year":"2017","unstructured":"Bi C, Zhang X, Lu T, Zhang X, Wang X, Meng B, et al. Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas. Haematologica. 2017;102:755\u201364.","journal-title":"Haematologica"},{"key":"4481_CR13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jgg.2020.04.006","volume":"47","author":"NM Hoang","year":"2020","unstructured":"Hoang NM, Rui L. DNA methyltransferases in hematological malignancies. J Genet Genomics. 2020;47:361\u201372.","journal-title":"J Genet Genomics"},{"key":"4481_CR14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126:291\u20139.","journal-title":"Blood"},{"key":"4481_CR15","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1158\/1535-7163.MCT-08-0411","volume":"7","author":"C Stresemann","year":"2008","unstructured":"Stresemann C, Bokelmann I, Mahlknecht U, Lyko F. Azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol Cancer Ther. 2008;7:2998\u20133005.","journal-title":"Mol Cancer Ther"},{"key":"4481_CR16","first-page":"3093","volume":"55","author":"T Murakami","year":"1995","unstructured":"Murakami T, Li X, Gong J, Bhatia U, Traganos F, Darzynkiewicz Z. Induction of apoptosis by 5-azacytidine: drug concentration-dependent differences in cell cycle specificity. Cancer Res. 1995;55:3093\u20138.","journal-title":"Cancer Res"},{"key":"4481_CR17","doi-asserted-by":"crossref","first-page":"2198098","DOI":"10.1080\/16078454.2023.2198098","volume":"28","author":"Y Du","year":"2023","unstructured":"Du Y, Li C, Yan J. The efficacy and safety of venetoclax and azacytidine combination treatment in patients with acute myeloid leukemia and myelodysplastic syndrome: systematic review and meta-analysis. Hematology. 2023;28:2198098.","journal-title":"Hematology"},{"key":"4481_CR18","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.2022016963","volume":"140","author":"AH Wei","year":"2022","unstructured":"Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, et al. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy. Blood. 2022;140:2754\u20136.","journal-title":"Blood"},{"key":"4481_CR19","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28398","volume":"67","author":"AC Winters","year":"2020","unstructured":"Winters AC, Maloney KW, Treece AL, Gore L, Franklin AK. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia. Pediatr Blood Cancer. 2020;67: e28398.","journal-title":"Pediatr Blood Cancer"},{"key":"4481_CR20","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","volume":"103","author":"I Aldoss","year":"2018","unstructured":"Aldoss I, Yang D, Aribi A, Ali H, Sandhu K, Al MM, et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia. Haematologica. 2018;103:e404\u20137.","journal-title":"Haematologica"},{"key":"4481_CR21","volume":"9","author":"F Varghese","year":"2014","unstructured":"Varghese F, Bukhari AB, Malhotra R, De A. IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLoS ONE. 2014;9: e96801.","journal-title":"PLoS ONE"},{"key":"4481_CR22","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282637","author":"LM Niswander","year":"2023","unstructured":"Niswander LM, Chung P, Diorio C, Tasian SK. Clinical responses in pediatric patients with relapsed\/refractory leukemia treated with azacitidine and venetoclax. Haematologica. 2023. https:\/\/doi.org\/10.3324\/haematol.2022.282637.","journal-title":"Haematologica"},{"key":"4481_CR23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature22393","volume":"547","author":"Y Wang","year":"2017","unstructured":"Wang Y, Gao W, Shi X, Ding J, Liu W, He H, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017;547:99\u2013103.","journal-title":"Nature"},{"key":"4481_CR24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41577-019-0228-2","volume":"20","author":"P Broz","year":"2020","unstructured":"Broz P, Pelegrin P, Shao F. The gasdermins, a protein family executing cell death and inflammation. Nat Rev Immunol. 2020;20:143\u201357.","journal-title":"Nat Rev Immunol"},{"key":"4481_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061292","author":"S Hafezi","year":"2021","unstructured":"Hafezi S, Rahmani M. Targeting BCL-2 in cancer: advances, challenges, and perspectives. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13061292.","journal-title":"Cancers"},{"key":"4481_CR26","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.bbamcr.2010.10.017","volume":"1813","author":"J Lindsay","year":"2011","unstructured":"Lindsay J, Esposti MD, Gilmore AP. Bcl-2 proteins and mitochondria\u2013specificity in membrane targeting for death. Biochim Biophys Acta. 2011;1813:532\u20139.","journal-title":"Biochim Biophys Acta"},{"key":"4481_CR27","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/sj.cdd.4400629","volume":"7","author":"Q Chen","year":"2000","unstructured":"Chen Q, Gong B, Almasan A. Distinct stages of cytochrome c release from mitochondria: evidence for a feedback amplification loop linking caspase activation to mitochondrial dysfunction in genotoxic stress induced apoptosis. Cell Death Differ. 2000;7:227\u201333.","journal-title":"Cell Death Differ"},{"key":"4481_CR28","doi-asserted-by":"publisher","DOI":"10.1101\/pdb.prot087361","author":"LC Crowley","year":"2016","unstructured":"Crowley LC, Christensen ME, Waterhouse NJ. Measuring mitochondrial transmembrane potential by TMRE staining. Cold Spring Harb Protoc. 2016. https:\/\/doi.org\/10.1101\/pdb.prot087361.","journal-title":"Cold Spring Harb Protoc."},{"key":"4481_CR29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102943","volume":"59","author":"S Missiroli","year":"2020","unstructured":"Missiroli S, Perrone M, Genovese I, Pinton P, Giorgi C. Cancer metabolism and mitochondria: finding novel mechanisms to fight tumours. EBioMedicine. 2020;59: 102943.","journal-title":"EBioMedicine"},{"key":"4481_CR30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41419-019-1441-4","volume":"10","author":"J Yu","year":"2019","unstructured":"Yu J, Li S, Qi J, Chen Z, Wu Y, Guo J, et al. Cleavage of GSDME by caspase-3 determines lobaplatin-induced pyroptosis in colon cancer cells. Cell Death Dis. 2019;10:193.","journal-title":"Cell Death Dis"},{"key":"4481_CR31","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2018.101084","volume":"25","author":"US Srinivas","year":"2019","unstructured":"Srinivas US, Tan B, Vellayappan BA, Jeyasekharan AD. ROS and the DNA damage response in cancer. Redox Biol. 2019;25: 101084.","journal-title":"Redox Biol"},{"key":"4481_CR32","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1038\/sj.onc.1211021","volume":"27","author":"MS Kim","year":"2008","unstructured":"Kim MS, Chang X, Yamashita K, Nagpal JK, Baek JH, Wu G, et al. Aberrant promoter methylation and tumor suppressive activity of the DFNA5 gene in colorectal carcinoma. Oncogene. 2008;27:3624\u201334.","journal-title":"Oncogene"},{"key":"4481_CR33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bbrc.2008.03.026","volume":"370","author":"MS Kim","year":"2008","unstructured":"Kim MS, Lebron C, Nagpal JK, Chae YK, Chang X, Huang Y, et al. Methylation of the DFNA5 increases risk of lymph node metastasis in human breast cancer. Biochem Biophys Res Commun. 2008;370:38\u201343.","journal-title":"Biochem Biophys Res Commun"},{"key":"4481_CR34","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1080\/07853890.2022.2099578","volume":"54","author":"M Li","year":"2022","unstructured":"Li M, Zhang D. DNA methyltransferase-1 in acute myeloid leukaemia: beyond the maintenance of DNA methylation. Ann Med. 2022;54:2011\u201323.","journal-title":"Ann Med"},{"key":"4481_CR35","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7\u201317.","journal-title":"Blood"},{"key":"4481_CR36","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-021-00507-5","volume":"6","author":"P Yu","year":"2021","unstructured":"Yu P, Zhang X, Liu N, Tang L, Peng C, Chen X. Pyroptosis: mechanisms and diseases. Signal Transduct Target Ther. 2021;6:128.","journal-title":"Signal Transduct Target Ther"},{"key":"4481_CR37","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.tcb.2017.05.005","volume":"27","author":"SB Kovacs","year":"2017","unstructured":"Kovacs SB, Miao EA. Gasdermins: effectors of pyroptosis. Trends Cell Biol. 2017;27:673\u201384.","journal-title":"Trends Cell Biol"},{"key":"4481_CR38","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109595","volume":"121","author":"Y Fang","year":"2020","unstructured":"Fang Y, Tian S, Pan Y, Li W, Wang Q, Tang Y, et al. Pyroptosis: a new frontier in cancer. Biomed Pharmacother. 2020;121: 109595.","journal-title":"Biomed Pharmacother"},{"key":"4481_CR39","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13045-020-00946-7","volume":"13","author":"R Tang","year":"2020","unstructured":"Tang R, Xu J, Zhang B, Liu J, Liang C, Hua J, et al. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. J Hematol Oncol. 2020;13:110.","journal-title":"J Hematol Oncol"},{"key":"4481_CR40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0966-842X(00)01936-3","volume":"9","author":"BT Cookson","year":"2001","unstructured":"Cookson BT, Brennan MA. Pro-inflammatory programmed cell death. Trends Microbiol. 2001;9:113\u20134.","journal-title":"Trends Microbiol"},{"key":"4481_CR41","doi-asserted-by":"crossref","first-page":"14128","DOI":"10.1038\/ncomms14128","volume":"8","author":"C Rogers","year":"2017","unstructured":"Rogers C, Fernandes-Alnemri T, Mayes L, Alnemri D, Cingolani G, Alnemri ES. Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic\/pyroptotic cell death. Nat Commun. 2017;8:14128.","journal-title":"Nat Commun"},{"key":"4481_CR42","doi-asserted-by":"crossref","first-page":"6066","DOI":"10.1158\/1078-0432.CCR-18-1478","volume":"24","author":"H Lu","year":"2018","unstructured":"Lu H, Zhang S, Wu J, Chen M, Cai MC, Fu Y, et al. Molecular targeted therapies elicit concurrent apoptotic and gsdme-dependent pyroptotic tumor cell death. Clin Cancer Res. 2018;24:6066\u201377.","journal-title":"Clin Cancer Res"},{"key":"4481_CR43","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1158\/2159-8290.CD-19-0672","volume":"10","author":"DA Erkes","year":"2020","unstructured":"Erkes DA, Cai W, Sanchez IM, Purwin TJ, Rogers C, Field CO, et al. Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis. Cancer Discov. 2020;10:254\u201369.","journal-title":"Cancer Discov"},{"key":"4481_CR44","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41419-020-2476-2","volume":"11","author":"L Hu","year":"2020","unstructured":"Hu L, Chen M, Chen X, Zhao C, Fang Z, Wang H, et al. Chemotherapy-induced pyroptosis is mediated by BAK\/BAX-caspase-3-GSDME pathway and inhibited by 2-bromopalmitate. Cell Death Dis. 2020;11:281.","journal-title":"Cell Death Dis"},{"key":"4481_CR45","volume":"35","author":"C de Torre-Minguela","year":"2021","unstructured":"de Torre-Minguela C, Gomez AI, Couillin I, Pelegrin P. Gasdermins mediate cellular release of mitochondrial DNA during pyroptosis and apoptosis. Faseb J. 2021;35: e21757.","journal-title":"Faseb J"},{"key":"4481_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-023-01060-3","author":"JP Liang","year":"2023","unstructured":"Liang JP, He YM, Cui YL, Sun YN, He GS, Zhu ZG, et al. Proteasomal inhibitors induce myeloma cell pyroptosis via the BAX\/GSDME pathway. Acta Pharmacol Sin. 2023. https:\/\/doi.org\/10.1038\/s41401-023-01060-3.","journal-title":"Acta Pharmacol Sin"},{"key":"4481_CR47","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41422-018-0090-y","volume":"28","author":"B Zhou","year":"2018","unstructured":"Zhou B, Zhang JY, Liu XS, Chen HZ, Ai YL, Cheng K, et al. Tom20 senses iron-activated ROS signaling to promote melanoma cell pyroptosis. Cell Res. 2018;28:1171\u201385.","journal-title":"Cell Res"},{"key":"4481_CR48","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1349-7006.2006.00351.x","volume":"98","author":"K Akino","year":"2007","unstructured":"Akino K, Toyota M, Suzuki H, Imai T, Maruyama R, Kusano M, et al. Identification of DFNA5 as a target of epigenetic inactivation in gastric cancer. Cancer Sci. 2007;98:88\u201395.","journal-title":"Cancer Sci"},{"key":"4481_CR49","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1002\/ijc.33390","volume":"148","author":"E De Schutter","year":"2021","unstructured":"De Schutter E, Croes L, Ibrahim J, Pauwels P, Op DBK, Vandenabeele P, et al. GSDME and its role in cancer: From behind the scenes to the front of the stage. Int J Cancer. 2021;148:2872\u201383.","journal-title":"Int J Cancer"},{"key":"4481_CR50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/leu.2013.242","volume":"28","author":"T Schoofs","year":"2014","unstructured":"Schoofs T, Berdel WE, Muller-Tidow C. Origins of aberrant DNA methylation in acute myeloid leukemia. Leukemia. 2014;28:1\u201314.","journal-title":"Leukemia"},{"key":"4481_CR51","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1101\/gad.184341.111","volume":"26","author":"JJ Trowbridge","year":"2012","unstructured":"Trowbridge JJ, Sinha AU, Zhu N, Li M, Armstrong SA, Orkin SH. Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes Dev. 2012;26:344\u20139.","journal-title":"Genes Dev"},{"key":"4481_CR52","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19:216\u201328.","journal-title":"Lancet Oncol"},{"key":"4481_CR53","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1038\/s41375-019-0612-8","volume":"33","author":"BA Jonas","year":"2019","unstructured":"Jonas BA, Pollyea DA. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia. 2019;33:2795\u2013804.","journal-title":"Leukemia"},{"key":"4481_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","volume":"58","author":"P Bose","year":"2017","unstructured":"Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma. 2017;58:1\u201317.","journal-title":"Leuk Lymphoma"},{"key":"4481_CR55","doi-asserted-by":"crossref","first-page":"14040","DOI":"10.1002\/jcp.28091","volume":"234","author":"L Nguyen","year":"2019","unstructured":"Nguyen L, Troadec E, Kalvala A, Kumar B, Hoang DH, Viola D, et al. The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML. J Cell Physiol. 2019;234:14040\u20139.","journal-title":"J Cell Physiol"},{"key":"4481_CR56","first-page":"234","volume":"138","author":"JB Lee","year":"2021","unstructured":"Lee JB, Khan DH, Hurren R, Xu M, Na Y, Kang H, et al. Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production. Blood. 2021;138:234\u201345.","journal-title":"Blood"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04481-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04481-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04481-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T21:29:58Z","timestamp":1700515798000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-04481-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,7]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4481"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-04481-0","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,7]]},"assertion":[{"value":"19 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Human samples have been performed following the Declaration of Helsinki and have been approved by the Ethics Committee of the Xiangya Hospital Central South University. Animal experiments were reviewed and approved by the Animal Care and Welfare Committee of Central South University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"606"}}